FR13C0013I1 - - Google Patents

Info

Publication number
FR13C0013I1
FR13C0013I1 FR13C0013C FR13C0013I1 FR 13C0013 I1 FR13C0013 I1 FR 13C0013I1 FR 13C0013 C FR13C0013 C FR 13C0013C FR 13C0013 I1 FR13C0013 I1 FR 13C0013I1
Authority
FR
France
Prior art keywords
glucagon
analogs
peptide
synthesis
identified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of FR13C0013I1 publication Critical patent/FR13C0013I1/fr
Application granted granted Critical
Publication of FR13C0013I2 publication Critical patent/FR13C0013I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR13C0013C 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon Active FR13C0013I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12
PCT/CA1997/000252 WO1997039031A1 (en) 1996-04-12 1997-04-11 Glucagon-like peptide-2 analogs

Publications (2)

Publication Number Publication Date
FR13C0013I1 true FR13C0013I1 (de) 2013-05-04
FR13C0013I2 FR13C0013I2 (fr) 2013-08-16

Family

ID=24530501

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0013C Active FR13C0013I2 (fr) 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon

Country Status (16)

Country Link
EP (5) EP2218734B1 (de)
JP (3) JP4148994B2 (de)
CN (1) CN1268640C (de)
AT (2) ATE478892T1 (de)
AU (1) AU733857B2 (de)
BR (1) BRPI9708566B8 (de)
CA (1) CA2251576C (de)
DE (2) DE69716905T2 (de)
DK (2) DK1231219T3 (de)
ES (2) ES2188929T3 (de)
FR (1) FR13C0013I2 (de)
HK (3) HK1033324A1 (de)
LU (1) LU92153I2 (de)
NZ (1) NZ332281A (de)
PT (2) PT906338E (de)
WO (1) WO1997039031A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
AU733857B2 (en) * 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
BR9808804A (pt) * 1997-05-16 2001-09-18 Ontario Inc Processos para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior incluindo o esÈfago e o estÈmago, para tratar um indivìduo para proliferar o tecido do trato gastrointestinal superior, para identificar peptìdeos utilizável para tratar condições inflamatórias, para identificar peptìdeos, utilizável para evitar ou melhorar as condições inflamatórias, utilizável para identificar peptìdeos capazes de proliferar tecido do trato gastrointestinal superior, para tratar profilaticamente um indivìduo, para melhorar o crescimento do tecido do trato gastrointestinal superior em um mamìfero, e para tratar um indivìduo para melhorar o funcionamento do trato gastrointestinal superior, kit, processos para promover o crescimento de tecido do trato gastrointestinal superior ou células, para tratar um paciente para restaurar o trato gastrointestinal superior, para determinar a atividade de um hormÈnio quando usado em combinação com glp-2, para tratar um indivìduo tendo úlceras peptìdicas
AU2712899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
AU7421598A (en) * 1998-05-11 1999-11-29 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
GB9930882D0 (en) * 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
EP1326630B1 (de) 2000-09-18 2008-05-28 Sanos Bioscience A/S Verwendung von glp-2-peptiden
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
JP2007526235A (ja) * 2003-08-21 2007-09-13 ノボ　ノルディスク　アクティーゼルスカブ グルカゴン様ペプチドの精製
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
ES2427150T3 (es) 2004-11-01 2013-10-29 Nps Pharmaceuticals, Inc. Tratamiento de pacientes con el síndrome del intestino corto con colon en continuidad
PL1877435T5 (pl) 2005-05-04 2021-09-27 Zealand Pharma A/S Analogi peptydu glukagonopodobnego 2 (GLP-2)
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
WO2008056155A1 (en) 2006-11-08 2008-05-15 Zealand Pharma A/S Selective glucagon-like-peptide-2 (glp-2) analogues
CN101824087A (zh) * 2009-03-05 2010-09-08 连云港恒邦医药科技有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (de) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
EP2314616A1 (de) * 2009-10-23 2011-04-27 Ferring B.V. GLP-2-Peptid-Agonisten
RU2012122162A (ru) * 2009-10-30 2013-12-10 Глитек,Инк. Гликолизированная форма аналога антигенного glp-1
WO2011133948A2 (en) 2010-04-22 2011-10-27 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US20130157954A1 (en) * 2010-05-11 2013-06-20 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
EP2694083A2 (de) 2011-04-01 2014-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide und pharmazeutische zusammensetzungen zur nasalen verabreichung für die behandlung von patienten mit angstzuständen und schlafstörungen
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
JP6298044B2 (ja) 2012-05-03 2018-03-20 ジーランド ファーマ アクティーゼルスカブ グルカゴン様ペプチド−２（ｇｌｐ−２）類似体
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
WO2014145718A2 (en) 2013-03-15 2014-09-18 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
EP3526242A1 (de) 2016-10-12 2019-08-21 University of Copenhagen Duale peptidagonisten von gipr und glp2r
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628683A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628682A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
CA3129576A1 (en) 2019-02-11 2020-08-20 Opko Biologics Ltd. Long-acting glp-2 analogs
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
US20230110689A1 (en) 2020-03-30 2023-04-13 Zealand Pharma A/S Agonist combination
WO2023111273A1 (en) * 2021-12-17 2023-06-22 Bainan Biotech Aps Peptide dual agonists of gipr and glp2r

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
EP0658568A1 (de) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-ähnliche, insalinotrope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
DE69738695D1 (de) 1996-03-01 2008-06-26 Novo Nordisk As Peptid zur Appetitzügelung, dessen Zusammensetzungen und Verwendung
AU733857B2 (en) 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
HK1050204A1 (en) 2003-06-13
DK0906338T3 (da) 2003-03-03
DE60142885D1 (de) 2010-10-07
AU2500297A (en) 1997-11-07
EP0906338B1 (de) 2002-11-06
BRPI9708566A (pt) 2000-01-04
ES2188929T3 (es) 2003-07-01
EP1231219A1 (de) 2002-08-14
DE69716905T2 (de) 2003-07-24
HK1033324A1 (en) 2001-08-24
JP2008184465A (ja) 2008-08-14
BRPI9708566B8 (pt) 2022-01-18
WO1997039031A1 (en) 1997-10-23
NZ332281A (en) 2000-03-27
LU92153I2 (fr) 2013-04-19
EP2275438A1 (de) 2011-01-19
EP0906338A1 (de) 1999-04-07
JP2000511881A (ja) 2000-09-12
CN1244872A (zh) 2000-02-16
PT1231219E (pt) 2010-11-30
DE69716905D1 (de) 2002-12-12
DK1231219T3 (da) 2010-12-20
PT906338E (pt) 2003-03-31
EP2218734A2 (de) 2010-08-18
CN1268640C (zh) 2006-08-09
EP2218734B1 (de) 2013-06-05
ES2351661T3 (es) 2011-02-09
JP4149497B2 (ja) 2008-09-10
JP4148994B2 (ja) 2008-09-10
BR9708566B1 (pt) 2012-09-04
EP1231219B1 (de) 2010-08-25
CA2251576C (en) 2012-08-21
FR13C0013I2 (fr) 2013-08-16
HK1147761A1 (en) 2011-08-19
EP2218734A3 (de) 2010-10-13
JP5019466B2 (ja) 2012-09-05
ATE478892T1 (de) 2010-09-15
JP2007204491A (ja) 2007-08-16
AU733857B2 (en) 2001-05-31
CA2251576A1 (en) 1997-10-23
EP2009024A1 (de) 2008-12-31
HK1050204B (zh) 2011-09-23
ATE227309T1 (de) 2002-11-15

Similar Documents

Publication Publication Date Title
FR13C0013I1 (de)
HUT64298A (en) Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
NO944644L (no) Fremstilling av 3,4,4-trisubstituert-piperidinyl-N-alkylkarboksylater og mellomprodukter
GR3024420T3 (en) Process for the preparation of oxetanones
HU9601857D0 (en) New benzyl-piperidine- or -tetrahydro-pyridine derivatives and processes for producing them
HU902288D0 (en) Process for producing new epimers of 1-alpha-hydroxy-d vitamin and their derivatives as well as pharmaceutical preparatives containing these compounds
AU7880494A (en) 5-methyluridine process for large-scale preparation of 2',3'-didehydro-3'-deoxythymidine (d4T)
MX9803672A (es) Nuevos derivados de fenilamidina, procedimiento para su preparacion y su utilizacion como medicamentos.
MY106522A (en) Arylaminocarbonyl compounds.
HU910506D0 (en) Process for producing 20, 21-dinoreburnamenine derivatives substituted inthe 9,10 and/or 11-location and pharmaceutical preparatives containing said compounds
ATE253902T1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
EP0034647A3 (en) 4-aryloxy- and 4-arylthio-3-phenylpiperidine derivatives, a process for the preparation of such compounds and their use as medicaments
HU9203928D0 (en) 6-sulfonyl-substituted 3-hydroxi-chromane derivatives and pharmaceutical preparatives containing them
MX9602804A (es) Derivados del 3-aril-alquenil-1,2,4-oxadiazol y su uso como parasiticidas para animales.
AU8516991A (en) Arg a human gene related to but distinct from abl proto-oncogene
EP0641335A4 (de) Durch freie radikale katalysierte synthese von benzoprostacyclinen.
HU910463D0 (en) Process for the production of medical preparation
HUP9600476A3 (en) Benzothiophene compounds, intermediates, process for their production, their use and compositions containing them
YU16590A (en) Process for preparing cyclical derivatives of 2',3'-seco-uridine
UA6626A (uk) Кормова добавка для корів
HU903473D0 (en) Process for the production of beta-cyclodextrine based inclusion as a medical product
ZA923165B (en) Novel anthelmintic milbemycin analogs of novel microorganisms
MN426A8 (en) Preparation of lactic-acidic product vitaminized by b12 using propion-acidic p.shermani bacteria
ZA911805B (en) 1-alkyl-,1 alkenyl-and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds,a process and intermediates for their preparation and their use as medicaments